Aldeyra Therapeutics, INC. (ALDX) — SEC Filings

Overview

Aldeyra Therapeutics, INC. (ALDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Aldeyra Therapeutics, Inc. announced on December 23, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 1 bullish, 37 neutral, 2 mixed. The dominant filing sentiment for Aldeyra Therapeutics, INC. is neutral.

Filing Type Overview

Aldeyra Therapeutics, INC. (ALDX) has filed 25 8-K, 6 10-Q, 2 DEF 14A, 1 10-K/A, 2 10-K, 2 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (40)

• Aldeyra Therapeutics Announces Board and Compensation Changes — 8-K · Dec 31, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. announced on December 23, 2025, changes related to its board of directors and executive compensation. The filing details the departur
• 8-K Filing — 8-K · Dec 16, 2025
• 8-K Filing — 8-K · Nov 13, 2025
• Aldeyra Narrows Q3 Loss by 49% on Steep R&D Cuts — 10-Q · Nov 5, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. reported a net loss of $7,688,341 for the three months ended September 30, 2025, a significant improvement from the $15,112,983 net l
• Aldeyra Therapeutics Files 8-K — 8-K · Oct 28, 2025 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on October 28, 2025, reporting other events and financial statements. The company, previously known as Aldexa Therapeuti
• Aldeyra Therapeutics Files 8-K — 8-K · Aug 19, 2025 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on August 19, 2025, reporting financial statements and exhibits. The company, incorporated in Delaware, is headquartered
• Aldeyra Narrows Q2 Loss to $20.1M Amid Reproxalap Review — 10-Q · Aug 7, 2025 Risk: high
  Aldeyra Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its prior-year periods, as it remains a clinica
• Aldeyra Therapeutics Files 8-K Report — 8-K · Jul 17, 2025 Risk: low
  On July 17, 2025, Aldeyra Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in
• Aldeyra Therapeutics Files 8-K — 8-K · Jun 26, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
• Aldeyra Therapeutics Files 8-K — 8-K · Jun 17, 2025 Risk: low
  On June 17, 2025, Aldeyra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Aldeyra Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 11, 2025 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on June 11, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 10, 2025. The
• Aldeyra Therapeutics Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported financial data related to its common stock and investments in
• Aldeyra Therapeutics Files 8-K — 8-K · May 6, 2025 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on events that occurred on May 5, 2025. The filing indicates it is a Regulation FD Disclosure,
• Aldeyra Therapeutics Files DEF 14A on Executive Compensation — DEF 14A · Apr 25, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. filed its DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, includi
• Aldeyra Therapeutics Announces Board and Executive Changes — 8-K · Apr 17, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. announced on April 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure o
• Aldeyra Therapeutics Files 8-K — 8-K · Apr 3, 2025 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on April 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
• Aldeyra Therapeutics Files 2024 Annual Report Amendment — 10-K/A · Mar 28, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on March 28, 2025
• Aldeyra Therapeutics Files 2024 10-K — 10-K · Feb 28, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Neuro
• Aldeyra Therapeutics Files 8-K: Material Agreement — 8-K · Nov 18, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. announced on November 15, 2024, that it entered into a material definitive agreement. The company also reported other events and file
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Aldeyra Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its busin
• Aldeyra Therapeutics Files 8-K — 8-K · Oct 3, 2024 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on October 3, 2024, reporting other events and financial statements. The company, previously known as Neuron Systems Inc
• Aldeyra Therapeutics Enters Material Agreement, Incurs Financial Obligation — 8-K · Oct 2, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. entered into a material definitive agreement on September 30, 2024, which also created a direct financial obligation for the registra
• Aldeyra Therapeutics Announces Board and Compensation Changes — 8-K · Sep 3, 2024 Risk: low
  Aldeyra Therapeutics, Inc. announced on August 29, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company re
• Aldeyra Therapeutics Files 8-K — 8-K · Aug 8, 2024 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on August 8, 2024, to report on other events and financial statements. The filing does not contain specific financial fi
• Aldeyra Therapeutics Enters Material Definitive Agreement — 8-K · Aug 1, 2024 Risk: medium
  On August 1, 2024, Aldeyra Therapeutics, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related t
• Aldeyra Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 1, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o
• Aldeyra Sells Subsidiary for $10M — 8-K · Jun 20, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. announced on June 20, 2024, that it has entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a
• Aldeyra Therapeutics Files 8-K — 8-K · Jun 13, 2024 Risk: low
  Aldeyra Therapeutics, Inc. filed an 8-K on June 13, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• Aldeyra Therapeutics Holds 2024 Annual Meeting — 8-K · Jun 7, 2024 Risk: low
  Aldeyra Therapeutics, Inc. announced on June 4, 2024, that it held its 2024 Annual Meeting of Stockholders. During the meeting, stockholders voted on the electi
• Aldeyra Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. (ALDX) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Aldeyra Therapeutics, Inc. filed a 10-Q report for the period end
• Amgen to Acquire Aldeyra Therapeutics for $6.1B — 8-K · Apr 25, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. announced on April 25, 2024, that it has entered into a definitive agreement to be acquired by Amgen Inc. for $6.1 billion, or $29.50
• Aldeyra Therapeutics Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 22, 2024 Risk: low
  Aldeyra Therapeutics, Inc. (ALDX) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. The 2024 Annual Meeting of Stockholders for Aldeyra Therapeu
• Aldeyra Sells Subsidiary for $50M — 8-K · Mar 28, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. announced on March 28, 2024, that it has entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a
• Aldeyra Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 7, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. (ALDX) filed a Annual Report (10-K) with the SEC on March 7, 2024. Aldeyra Therapeutics, Inc. filed its 2023 Form 10-K on March 7, 20
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Aldeyra Therapeutics Files 8-K for Reg FD Disclosure — 8-K · Feb 13, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. filed an 8-K on February 13, 2024, to disclose information under Regulation FD and to include Financial Statements and Exhibits. This
• SC 13G Filing — SC 13G · Feb 13, 2024
• BlackRock Discloses 6.0% Passive Stake in Aldeyra Therapeutics — SC 13G · Jan 29, 2024
  BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds 3,747,940 shares of Aldeyra Therapeutics, Inc. com
• Aldeyra Therapeutics Updates Corporate Contact Info in 8-K Filing — 8-K · Jan 4, 2024
  Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K on January 4, 2024, to update its corporate information, including its business address at 131 Hartwell Avenue, S

Risk Profile

Risk Assessment: Of ALDX's 33 recent filings, 1 were flagged as high-risk, 19 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Aldeyra Therapeutics, INC.'s most recent 10-Q filing (Nov 5, 2025):

• Revenue: Not Disclosed
• Net Income: -$7,688,341
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: $59,340,599
• Operating Margin: Not Disclosed
• Total Assets: $77,801,012
• Total Debt: Not Disclosed

Key Executives

• Todd C. Brady, M.D., Ph.D.

Industry Context

Aldeyra Therapeutics operates in the highly competitive biotechnology sector, focusing on developing treatments for ocular and other inflammatory diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory requirements. Key trends include the pursuit of novel therapeutic modalities and the increasing demand for treatments addressing unmet medical needs in ophthalmology and immunology.

Top Tags

8-K (8) · pharmaceuticals (4) · financials (4) · filing (4) · 10-Q (4) · sec-filing (3) · disclosure (3) · regulatory (3) · executive-compensation (3) · governance (3)

Key Numbers

• SEC File Number: 001-36332 — Identifies the company's filing history with the SEC.
• Report Date: 20251223 — Indicates the date of the earliest event reported in this 8-K filing.
• Net Loss (Q3 2025): $7.69M — Decreased by 49.1% from $15.11M in Q3 2024
• Net Loss (9 Months 2025): $27.39M — Decreased by 31.6% from $40.04M in 9 Months 2024
• R&D Expenses (Q3 2025): $5.43M — Decreased by 56.4% from $12.44M in Q3 2024
• R&D Expenses (9 Months 2025): $21.36M — Decreased by 36.4% from $33.59M in 9 Months 2024
• Cash & Cash Equivalents (Sept 30, 2025): $59.34M — Increased from $54.53M at Dec 31, 2024
• Total Stockholders' Equity (Sept 30, 2025): $49.24M — Decreased from $71.00M at Dec 31, 2024
• Accumulated Deficit (Sept 30, 2025): $477.50M — Increased from $450.11M at Dec 31, 2024
• Common Shares Outstanding (Nov 4, 2025): 60,162,773 — Increased from 59,648,278 at Dec 31, 2024
• Commission File Number: 001-36332 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 20-1968197 — Company's tax identification number.
• Revenue: $0 — for Q2 and H1 2025, consistent with prior periods
• Net Loss (Q2 2025): $20.1M — decreased from $24.8M in Q2 2024
• Net Loss (H1 2025): $41.5M — decreased from $49.1M in H1 2024

Related Companies

AMGN

Frequently Asked Questions